Reactive Biosciences of Durham (formerly Boragen) disclosed in an SEC filing that it has raised $4 million in debt. The company last raised more than $23 million in equity funding in the fall of 2022.
Read More
Reactive Biosciences, formerly Boragen, has raised about $23.5 million in equity funding. But a filing shows the company may raise as much as $40 million.
Read More
RESEARCH TRIANGLE PARK – Boron’s value as a plant nutrient is well documented, but it has other properties that make it attractive for crop protection. Products based on the periodic table’s fifth element may be able to address targets that have eluded traditional chemistry. Also, boron leaves no residue on...
Read More
Boragen, a boron-based discovery platform company based in the Research Triangle Park, has won a $300,500 Phase I Small Business Innovation Research grant for research on controlling malaria. Here are the details.
Read More
Startup Boragen just closed on $2 million in new financing. Now it has in hand a research-and-development deal for work in animal health.
Read More
In 2015, a team of chemists — Dr. Stephen Benkovic, Dr. Lucy Shapiro, Dr. Paul Schimmel, Dr. Gerald Fink, and Dr. C. Tony Liu – founded the Durham-based company as a spinout of Pennsylvania State University.
Read More
Boragen, a molecule development company, has raised $3 million by selling debt and wants to raise another $1.25 million.
Read More
